Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 4;29(5):566-578.
doi: 10.5603/rpor.102820. eCollection 2024.

Reirradiation of gliomas with hypofractionated stereotactic radiotherapy: efficacy and tolerance analysis at a single center

Mercedes López González  1 , Raquel Ciervide  1 , Ovidio Hernando Requejo  1 , Ángel Montero Luis  1 , Beatriz Álvarez Rodriguez  1 , Emilio Sánchez Saugar  1 , Leyre Alonso Iracheta  2 , Xin Chen  1 , Mariola Garcia-Aranda  1 , Daniel Zucca  2 , Jeannette Valero  1 , Rosa Alonso  1 , Pedro Fernández-Letón  2 , Carmen Rubio  1
Affiliations

Reirradiation of gliomas with hypofractionated stereotactic radiotherapy: efficacy and tolerance analysis at a single center

Mercedes López González et al. Rep Pract Oncol Radiother. .

Abstract

Background: Recurrent high-grade gliomas present a therapeutic challenge. Repeat surgery, re-irradiation, and systemic therapy have been explored, with re-irradiation requiring precise tumor relapse delineation and advanced dosimetric techniques. This study aims to evaluate the effectiveness and tolerability of re-irradiation using Hypofractionated Stereotactic Radiation (HFSRT) schedules.

Materials and methods: In a retrospective analysis from 2011 to 2021, 52 adult patients with recurrent high-grade gliomas were examined, including 42.3% with glioblastoma, 32.5% with grade 3 gliomas, and 25% with grade 2 gliomas as initial diagnosis. All received prior radiotherapy at doses ranging from 54-60 Gy, with a median time to tumor relapse of 19.8 months. Salvage surgery was performed in 42.3% of cases, with a median interval of 22.45 months between radiation courses. Re-irradiation doses were 30 Gy in 5 fractions for 54% and 40 Gy in 10 fractions for 46%. Concurrent systemic treatments included temozolomide (30.8%), nevacizumab (27%), or none (35%).

Results: In-field and out-field tumor progression occurred in 65.4% and 25% of patients, with median times to local and distant progression of 5.17 and 4.57 months. Median overall survival (OS) from re-irradiation was 12 months. Univariate analysis showed a trend favoring 30 Gy in 5 fractions for disease progression-free survival (DPFS). Treatment was generally well-tolerated, with only 5.7% experiencing acute Grade-3 toxicity, and symptomatic radionecrosis occurred in 2 patients.

Conclusion: Re-irradiation using HFSRT for recurrent high-grade gliomas is viable and well-tolerated, demonstrating survival rates comparable to existing literature. These findings underscore the potential of HFSRT in managing recurrent high-grade gliomas.

Keywords: glioblastoma; high grade gliomas; hypofractionation; reirradiation; stereotactic radiation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Progression free survival
Figure 2
Figure 2
Overall survival according to tumor grade
Figure 3
Figure 3
Computed tomography-magnetic resonance imaging (CT-MRI). Registration and fusion
Figure 4
Figure 4
Treatment planning
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19(suppl_5):v1–v88. doi: 10.1093/neuonc/nox158. - DOI - PMC - PubMed
    1. Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406. doi: 10.3322/caac.21693. - DOI - PubMed
    1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820. doi: 10.1007/s00401-016-1545-1. - DOI - PubMed
    1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–186. doi: 10.1038/s41571-020-00447-z. - DOI - PMC - PubMed

LinkOut - more resources